Analysts expect Iovance Biotherapeutics Inc (NASDAQ:IOVA) to announce earnings of ($0.35) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Iovance Biotherapeutics’ earnings, with estimates ranging from ($0.43) to ($0.18). Iovance Biotherapeutics reported earnings per share of ($0.36) in the same quarter last year, which suggests a positive year-over-year growth rate of 2.8%. The firm is scheduled to report its next quarterly earnings results on Tuesday, November 5th.
On average, analysts expect that Iovance Biotherapeutics will report full year earnings of ($1.38) per share for the current fiscal year, with EPS estimates ranging from ($1.60) to ($0.84). For the next financial year, analysts expect that the firm will report earnings of ($1.54) per share, with EPS estimates ranging from ($2.41) to ($0.59). Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Iovance Biotherapeutics.
Iovance Biotherapeutics (NASDAQ:IOVA) last released its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($0.38) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.29) by ($0.09).
IOVA has been the topic of a number of recent research reports. Wells Fargo & Co raised their price objective on shares of Iovance Biotherapeutics from $23.00 to $32.00 and gave the company an “outperform” rating in a research note on Thursday, May 23rd. ValuEngine raised shares of Iovance Biotherapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, May 23rd. Zacks Investment Research raised shares of Iovance Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Friday, August 9th. BidaskClub cut shares of Iovance Biotherapeutics from a “buy” rating to a “hold” rating in a research note on Friday, July 26th. Finally, B. Riley set a $24.00 price objective on shares of Iovance Biotherapeutics and gave the company a “buy” rating in a research note on Friday, May 17th. Two investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $28.45.
IOVA stock traded down $0.50 during midday trading on Thursday, reaching $20.02. The company’s stock had a trading volume of 1,322,889 shares, compared to its average volume of 1,447,800. Iovance Biotherapeutics has a 52 week low of $7.26 and a 52 week high of $26.59. The stock has a market capitalization of $2.52 billion, a PE ratio of -15.76 and a beta of 1.81. The company has a debt-to-equity ratio of 0.01, a quick ratio of 12.14 and a current ratio of 12.15. The stock’s 50-day moving average price is $23.98.
Institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. raised its holdings in shares of Iovance Biotherapeutics by 5.9% during the second quarter. BlackRock Inc. now owns 9,355,972 shares of the biotechnology company’s stock worth $229,410,000 after acquiring an additional 520,445 shares during the period. Vanguard Group Inc. grew its position in shares of Iovance Biotherapeutics by 46.3% in the 2nd quarter. Vanguard Group Inc. now owns 8,491,841 shares of the biotechnology company’s stock valued at $208,220,000 after acquiring an additional 2,688,963 shares during the period. Price T Rowe Associates Inc. MD grew its position in shares of Iovance Biotherapeutics by 72.5% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 6,023,903 shares of the biotechnology company’s stock valued at $147,706,000 after acquiring an additional 2,531,169 shares during the period. Bank of America Corp DE boosted its holdings in shares of Iovance Biotherapeutics by 48.2% during the 2nd quarter. Bank of America Corp DE now owns 3,084,339 shares of the biotechnology company’s stock worth $75,627,000 after buying an additional 1,002,500 shares during the period. Finally, Northern Trust Corp boosted its holdings in shares of Iovance Biotherapeutics by 0.7% during the 2nd quarter. Northern Trust Corp now owns 1,391,601 shares of the biotechnology company’s stock worth $34,122,000 after buying an additional 9,910 shares during the period. Institutional investors own 95.67% of the company’s stock.
Iovance Biotherapeutics Company Profile
Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma.
Featured Article: Trading Penny Stocks
Get a free copy of the Zacks research report on Iovance Biotherapeutics (IOVA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.